In most cases, no. Suboxone's active ingredient, buprenorphine, is a synthetic opioid that standard 5 panel and 10 panel urine opiate screens are not built to catch. A buprenorphine result only appears when the specimen is run against a dedicated BUP (buprenorphine) test strip or an expanded panel that specifically includes buprenorphine and its metabolite, norbuprenorphine. For employers, clinics, and treatment centers, understanding that gap is the difference between a testing program that supports medication assisted treatment (MAT) and one that accidentally screens out patients who are following a legitimate prescription.
What Suboxone and Buprenorphine Are
Suboxone is a brand name sublingual film that combines buprenorphine, a partial opioid agonist, with naloxone, an opioid antagonist added to deter misuse by injection. Per the FDA approved prescribing information on file with the National Library of Medicine, "SUBOXONE sublingual film is indicated for treatment of opioid dependence," and the product "contains buprenorphine, a Schedule III controlled substance under the Controlled Substances Act." Prescribing is restricted to qualified providers under the Drug Addiction Treatment Act, and the medication is meant to be used alongside counseling and psychosocial support as part of a structured MAT program.
Because buprenorphine is itself an opioid, patients and employers both reasonably ask whether it will trigger a positive result on a routine workplace or clinical drug screen. The short answer is that it will not, unless the test is specifically designed to look for it.
Why the Standard Opiate Panel Misses It
Standard 5 panel and 10 panel immunoassay screens target a specific, defined list of opioids. That list is easiest to see in the federally regulated drug testing space. Under 49 CFR 40.85, the drug testing panel required for DOT regulated employers covers marijuana metabolites, cocaine metabolite, opioids limited to codeine, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and 6-acetylmorphine, phencyclidine (PCP), and amphetamine, methamphetamine, MDMA, and MDA. Buprenorphine does not appear anywhere on that list, and it is not part of the mandatory DOT testing panel.
That is not an oversight. Buprenorphine is chemically distinct from the natural and semi-synthetic opioids that standard opiate immunoassays are calibrated to detect, so it largely does not cross react with those tests. A urine testing review published through the National Institutes of Health's PubMed Central confirms that standard opiate immunoassay screens do not reliably detect buprenorphine, which is why a separate, buprenorphine specific assay is required to identify it. In practice, an employee taking Suboxone as prescribed can pass a routine opiate panel cleanly, because the test was never designed to look for that molecule in the first place.
The Dedicated BUP Panel and Its Cutoff
To screen for buprenorphine use, an employer or clinic has to add a dedicated BUP test to the panel, either as a standalone dip card or as an additional strip built into a multi panel cup. These devices use an immunoassay calibrated specifically to buprenorphine and norbuprenorphine rather than to morphine type opioids.
Cutoff concentrations for BUP immunoassays vary by manufacturer, but published validation research available through the National Institutes of Health has examined cutoffs in the 5 to 10 ng/mL range and found that raising the screening cutoff to 10 ng/mL improved diagnostic accuracy by reducing false positives caused by cross-reacting opioids and their metabolites. That is why many BUP-specific immunoassays on the market today are built around a cutoff near 10 ng/mL for the initial screen, with laboratory confirmation run at a lower threshold to catch borderline specimens. As with any presumptive test, a non-negative BUP screen is not a diagnosis. It should be sent to a certified laboratory for confirmatory testing by gas chromatography-mass spectrometry or liquid chromatography-mass spectrometry before any decision is made.
Detection Windows
Detection windows for buprenorphine depend on dose, frequency of use, and individual metabolism, so no single number applies to every patient. Research on urine detection compiled through the National Institutes of Health places buprenorphine's own detection window at roughly 1 to 7 days after last use, while its metabolite, norbuprenorphine, can remain detectable for up to 14 days. Patients on a stable daily MAT dose will typically test positive on a BUP panel throughout treatment, which is expected and clinically appropriate, not a red flag on its own.
| Feature | Standard 5/10 panel opiate screen | Dedicated BUP panel |
|---|---|---|
| Analytes targeted | Codeine, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, 6-AM | Buprenorphine and norbuprenorphine |
| Detects Suboxone use | No, buprenorphine does not reliably cross react | Yes, when included on the cup, cup strip, or dip card |
| Typical immunoassay cutoff | 2,000 ng/mL initial for morphine group opiates | Commonly around 10 ng/mL initial screen |
| Included in DOT 49 CFR 40.85 panel | Opioid analytes listed are included | Not included, buprenorphine is not a DOT panel drug |
| Best used for | General workplace, pre-employment, DOT-regulated testing | MAT compliance monitoring, pain management, addiction treatment centers, non-DOT workplace policies that screen for diverted use |
Employers building a program around addiction recovery or MAT monitoring generally look to addiction recovery drug and alcohol testing supplies or a broader drug and alcohol testing solution for rehab centers that includes a BUP strip rather than relying on a standard opiate cup alone. Pain management clinics that prescribe or monitor buprenorphine face a similar gap and typically source from a pain management and pain clinic drug testing collection built around expanded panels.
Why MAT-Friendly Policy Design Matters
A workplace testing policy that flags every buprenorphine positive as a violation, without any process for disclosing a legitimate prescription, can create legal exposure and undermines recovery. Guidance published by the U.S. Equal Employment Opportunity Commission explains that people in treatment or recovery for opioid use disorder, including those taking a legally prescribed medication such as buprenorphine or methadone through a MAT program, are protected from discrimination under the Americans with Disabilities Act. As the agency states, "if you are taking an opioid medication as directed in a MAT program, then you have a valid prescription and your use of the medication is legal," and employers "should give anyone subject to drug testing an opportunity to provide information about lawful drug use that may cause a drug test result that shows opioid use." The EEOC also notes that reasonable accommodations, such as a modified schedule to attend treatment or counseling, may be required where they would let the employee perform the job safely, though employers are not required to excuse illegal drug use or lower performance and safety standards.
None of this prevents an employer from maintaining a drug-free workplace policy or from testing for buprenorphine where there is a legitimate safety or compliance reason to do so, such as monitoring for diversion in a treatment setting or verifying appropriate use in a pain management practice. It does mean the policy should route non-negative results through a verification step rather than an automatic adverse action, giving employees a documented channel to disclose a valid prescription. Employers who need that broader framework, from pre-employment through ongoing monitoring, typically build it around a workplace drug testing solution for employers, and DOT-regulated carriers layer the required panel on top of a dedicated DOT drug and alcohol testing program for transportation companies, since buprenorphine sits outside the drugs DOT testing is required to cover. For a deeper look at building a compliant, MAT-aware policy, see ASC's article on MAT programs and drug testing compliance.
The MRO's Role in Reviewing a Buprenorphine Result
When a BUP screen comes back non-negative and is confirmed positive by the laboratory, the result should go to a Medical Review Officer or reviewing physician before it reaches a hiring or discipline decision. The MRO's job is to contact the individual, review any prescription documentation, and determine whether the result has a legitimate medical explanation, such as an active MAT prescription, before the result is reported to the employer. Because buprenorphine is not one of the drugs listed under 49 CFR 40.85, this review does not fall under the federal MRO process that governs DOT testing. For non-DOT employers, clinics, and treatment programs, the same verification principle still applies as a matter of sound policy and legal risk management: build a physician or MRO review step into the process before any confirmed BUP result affects someone's job or treatment status.
Compliance note: Drug test screening devices, including BUP panels, are preliminary tools designed to produce a presumptive result. They do not diagnose opioid use disorder, do not identify a specific individual's use with certainty, and do not replace confirmatory laboratory testing. Any non-negative screening result should be sent to a certified laboratory for confirmation before any employment, clinical, or legal action is taken. This article is for general informational purposes only and is not medical, legal, or compliance advice; consult a qualified MRO, physician, or attorney for guidance specific to your program.
Frequently Asked Questions
Does a standard 5 panel or 10 panel drug test detect Suboxone or buprenorphine?
No. Standard opiate immunoassay panels are built to detect codeine, morphine, and related semi-synthetic opioids, not buprenorphine, which is chemically distinct and does not reliably cross react with those tests. Detecting Suboxone use requires a separate, dedicated BUP test strip or panel.
What cutoff level is used for a buprenorphine (BUP) screening test?
Cutoffs vary by manufacturer, but published validation research has evaluated buprenorphine immunoassay cutoffs in the 5 to 10 ng/mL range and found that a 10 ng/mL initial cutoff improves accuracy by reducing false positives from cross-reacting opioids. Any non-negative screen should still be confirmed at a certified laboratory.
How long does buprenorphine stay detectable in urine?
Detection windows vary with dose, frequency of use, and individual metabolism. Research indicates buprenorphine itself is typically detectable in urine for roughly 1 to 7 days after last use, while its metabolite, norbuprenorphine, can remain detectable for up to 14 days. Patients on a stable daily MAT dose will generally test positive throughout treatment.
Can an employee be disciplined for testing positive for buprenorphine if they have a legitimate Suboxone prescription?
Federal guidance from the EEOC states that people taking a legally prescribed MAT medication such as buprenorphine are protected from discrimination under the Americans with Disabilities Act and should be given an opportunity to disclose lawful drug use that explains a positive result. Employers can still maintain drug-free workplace policies and safety standards, but a documented MRO or physician review step should be part of the process before any adverse action is taken.
